Showing results (351-360 of 447) with videos related to
Sort By:
Pageof 45
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 25, 2022
External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell CancerBhavna Oza, Tim Eisen, Eleni Frangou, et al.The New England Journal of Medicine|April 21, 2015
Pembrolizumab versus Ipilimumab in Advanced MelanomaCaroline Robert, Jacob Schachter, Georgina V Long, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2018
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III MelanomaAxel Hauschild, Reinhard Dummer, Dirk Schadendorf, et al.Journal for Immunotherapy of Cancer|February 26, 2025
Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020Paolo A Ascierto, Hao Tang, Sonia Dolfi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 13, 2024
First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial DataGeorgina V Long, Evan J Lipson, F Stephen Hodi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2017
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III TrialJames Larkin, David Minor, Sandra D'Angelo, et al.European Journal of Cancer (Oxford, England : 1990)|July 2, 2021
Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapyAdriana Hepner, Victoria G Atkinson, James Larkin, et al.European Journal of Cancer Care|May 4, 2021
'This is not part of my life plan': A qualitative study on the psychosocial experiences and practical challenges in young adults with cancer age 25 to 39 years at diagnosisEmma Lidington, Carla Vlooswijk, Kate Stallard, et al.European Journal of Cancer (Oxford, England : 1990)|May 15, 2017
Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysisChristian U Blank, James Larkin, Ana M Arance, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 20, 2026
CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal CancerFrancesca Jackson-Spence, James Larkin, Poulam Patel, et al.Pageof 45